Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 2Withdrawn 1Not yet recruiting 1Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 8Thoracic 4Gynecologic 3Dermatologic 3Sarcoma 2Genitourinary 2Other solid neoplasm 1NET 1Head & Neck 1Endocrine 1CNS 1

Conditions

Brain Neoplasms 152Glioblastoma 147Glioma 94Neuroblastoma 50Medulloblastoma 33Central Nervous System Neoplasms 27Astrocytoma 27Neoplasms 24Ependymoma 23Sarcoma 22Carcinoma, Non-Small-Cell Lung 22Neurofibromatosis 1 20Melanoma 20Breast Neoplasms 20Rhabdomyosarcoma 18Osteosarcoma 18Sarcoma, Ewing 16Lung Neoplasms 16Gliosarcoma 16Rhabdoid Tumor 15Oligodendroglioma 15Wilms Tumor 13Meningioma 13Hepatoblastoma 13Diffuse Intrinsic Pontine Glioma 13Recurrence 12Neurofibroma, Plexiform 11Neoplasm Metastasis 11Meningeal Carcinomatosis 11Lymphoma, Non-Hodgkin 11

Interventions

pembrolizumab 1Specimen Handling 1Magnetic Resonance Spectroscopy 1Diffusion Tensor Imaging 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Turcot syndrome × CNS × Clear all
NCT02359565 2026-05-13

Pembrolizumab in Treating Younger Patients With Recurrent, Progressive, or Refractory High-Grade Gliomas, Diffuse Intrinsic Pontine Gliomas, Hypermutated Brain Tumors, Ependymoma or Medulloblastoma

National Cancer Institute (NCI)

Phase 1 Active not recruiting
71 enrolled
CNSGastrointestinal

Familial ependymoma, Turcot syndrome, Diffuse Intrinsic Pontine Glioma, Brain Neoplasms, Colorectal Neoplasms, Hereditary Nonpolyposis, Ependymoma, Glioma, Medulloblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡